BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 46.0
(-2.17%)
JPY 46.0
(-2.17%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 72 Thousand | 5.28 Million | 15.4 Million | 2.5 Million | 11.3 Million | 155.8 Million |
| Cost of Revenue | 413 Thousand | 1.89 Million | 3.31 Million | 1.14 Million | 4.46 Million | 70.7 Million |
| Gross Profit | -341 Thousand | 3.38 Million | 12.09 Million | 1.35 Million | 6.83 Million | 85.1 Million |
| Operating Expenses | 1.15 Billion | 1.47 Billion | 1.48 Billion | 1.73 Billion | 1.83 Billion | 1.75 Billion |
| Selling, General and Administrative Expenses | 379.18 Million | 285.25 Million | 317.15 Million | 259.02 Million | 286.85 Million | 308.82 Million |
| Research and Development Expenses | 775.55 Million | 1.16 Billion | 1.13 Billion | 1.4 Billion | 1.48 Billion | 1.38 Billion |
| Other Expenses | - | 241 Thousand | 89 Thousand | 98 Thousand | 301 Thousand | -10.26 Million |
| Cost and Expenses | 1.15 Billion | 1.47 Billion | 1.49 Billion | 1.73 Billion | 1.83 Billion | 1.82 Billion |
| Operating Income | -1.15 Billion | -1.46 Billion | -1.47 Billion | -1.73 Billion | -1.82 Billion | -1.66 Billion |
| Interest Expense | 1.39 Million | 61 Thousand | 362 Thousand | 9.09 Million | - | - |
| Income Tax Expense | 1.9 Million | 1.9 Million | 2.42 Million | 2.42 Million | -2.08 Million | 3.78 Million |
| Earnings before Tax | -1.16 Billion | -1.48 Billion | -1.48 Billion | -1.71 Billion | -1.85 Billion | -1.88 Billion |
| Net Income | -1.16 Billion | -1.48 Billion | -1.48 Billion | -1.71 Billion | -1.85 Billion | -1.88 Billion |
| Earnings Per Share Basic | -18.21 | -24.90 | -28.55 | -36.14 | -44.20 | -44.95 |
| Earnings Per Share Diluted | -18.21 | -24.90 | -28.55 | -36.14 | -44.20 | -44.95 |
| Weighted Average Shares Outstanding | 64.16 Million | 59.66 Million | 51.99 Million | 47.58 Million | 42.03 Million | 41.91 Million |
| Weighted Average Shares Outstanding (Diluted) | 64.16 Million | 59.66 Million | 51.99 Million | 47.58 Million | 42.03 Million | 41.91 Million |
| Gross Margin | -4.74 | 0.64 | 0.78 | 0.54 | 0.60 | 0.55 |
| EBIT Margin | -16.19 Thousand | -275.95 | -93.88 | -673.94 | -153.01 | -8.86 |
| Profit Margin | -16.22 Thousand | -281.37 | -96.33 | -686.75 | -164.40 | -12.09 |
| EBITDA | -1.16 Billion | -1.46 Billion | -1.44 Billion | -1.65 Billion | -1.76 Billion | -1.58 Billion |
| Earnings Before Tax Margin | -16.04 Thousand | -277.85 | -95.80 | -692.01 | -161.71 | -10.69 |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 28 Thousand | 72 Thousand | 5000.00 | 23 Thousand | 28 Thousand | 16 Thousand |
| Cost of Revenue | 7000.00 | 413 Thousand | 87 Thousand | 5000.00 | 7000.00 | 4000.00 |
| Gross Profit | 21 Thousand | -341 Thousand | -82 Thousand | 18 Thousand | 21 Thousand | 12 Thousand |
| Operating Expenses | 326.99 Million | 1.15 Billion | 207.82 Million | 396.62 Million | 257.15 Million | 293.44 Million |
| Selling, General and Administrative Expenses | 326.99 Million | - | 79.84 Million | 112.67 Million | 86.12 Million | 100.53 Million |
| Research and Development Expenses | - | - | 127.97 Million | 283.68 Million | 171.03 Million | 192.86 Million |
| Other Expenses | -326.99 Million | 196 Thousand | 100 Thousand | -90 Thousand | - | 186 Thousand |
| Cost and Expenses | 327 Million | 1.15 Billion | 207.91 Million | 396.62 Million | 257.16 Million | 293.45 Million |
| Operating Income | -326.97 Million | -1.15 Billion | -207.9 Million | -396.6 Million | -257.13 Million | -293.43 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 475 Thousand | 1.9 Million | 475 Thousand | 475 Thousand | 475 Thousand | 475 Thousand |
| Earnings before Tax | -329.94 Million | -1.16 Billion | -213.84 Million | -399.36 Million | -257.69 Million | -295.28 Million |
| Net Income | -330.42 Million | -1.16 Billion | -214.31 Million | -399.84 Million | -258.16 Million | -295.75 Million |
| Earnings Per Share Basic | -4.66 | - | -3.17 | -6.32 | -4.10 | -4.70 |
| Earnings Per Share Diluted | -4.66 | - | -3.17 | -6.32 | -4.10 | -4.70 |
| Weighted Average Shares Outstanding | 70.96 Million | 64.16 Million | 67.6 Million | 63.26 Million | 62.89 Million | 62.89 Million |
| Weighted Average Shares Outstanding (Diluted) | 70.96 Million | 64.16 Million | 67.6 Million | 63.26 Million | 62.89 Million | 62.89 Million |
| Gross Margin | 0.75 | -4.74 | -16.40 | 0.78 | 0.75 | 0.75 |
| EBIT Margin | -11.67 Thousand | - | -41.56 Thousand | -17.09 Thousand | -9183.39 | -18.25 Thousand |
| Profit Margin | -11.8 Thousand | -16.22 Thousand | -42.86 Thousand | -17.38 Thousand | -9220.21 | -18.48 Thousand |
| EBITDA | -326.97 Million | - | -207.82 Million | -393.24 Million | -257.13 Million | -292.02 Million |
| Earnings Before Tax Margin | -11.67 Thousand | -16.04 Thousand | -41.58 Thousand | -17.24 Thousand | -9183.36 | -18.33 Thousand |
CLPBY
8129
6325
0H8I
BOKF
2324